Meeting NewsVideo

VIDEO: BLU-667, avapritinib highlight Blueprint Medicines pipeline

CHICAGO — Anthony “Andy” Boral, MD, PhD, chief medical officer at Blueprint Medicines, spoke with HemOnc Today at ASCO Annual Meeting about key study results the company presented and the investigational agents in its pipeline.

Boral highlighted data on BLU-667,a RET inhibitor evaluated in patients with non-small cell lung cancer or medullary thyroid cancer driven by alterations in the RET gene. The company plans to submit a new drug application seeking regulatory approval for this agent in the first quarter of next year, Boral said.

Boral also spoke about avapritinib, a potent selective KIT and PDGFR-alpha inhibitor in development for patients with advanced gastrointestinal stromal tumors. Data presented at ASCO will support a new drug application for this agent that is scheduled to be submitted to FDA this month, Boral said.

Avapritinib also is under investigation for patients with advanced systemic mastocytosis, with additional data from that setting scheduled for presentation at this year’s European Hematology Association Annual Congress. – by Mark Leiser

CHICAGO — Anthony “Andy” Boral, MD, PhD, chief medical officer at Blueprint Medicines, spoke with HemOnc Today at ASCO Annual Meeting about key study results the company presented and the investigational agents in its pipeline.

Boral highlighted data on BLU-667,a RET inhibitor evaluated in patients with non-small cell lung cancer or medullary thyroid cancer driven by alterations in the RET gene. The company plans to submit a new drug application seeking regulatory approval for this agent in the first quarter of next year, Boral said.

Boral also spoke about avapritinib, a potent selective KIT and PDGFR-alpha inhibitor in development for patients with advanced gastrointestinal stromal tumors. Data presented at ASCO will support a new drug application for this agent that is scheduled to be submitted to FDA this month, Boral said.

Avapritinib also is under investigation for patients with advanced systemic mastocytosis, with additional data from that setting scheduled for presentation at this year’s European Hematology Association Annual Congress. – by Mark Leiser

    See more from ASCO Annual Meeting